Efficacy and safety of pentosan polysulfate sodium in people with symptomatic knee osteoarthritis and dyslipidaemia: protocol of the MaRVeL trial
https://pubmed.ncbi.nlm.nih.gov/38777590/
ACTRN12621000654853
A Double-Blind, RandoMised, Placebo-Controlled Study to Assess the
Efficacy and Safety of oRal deliVery of sodium Pentosan Polysulfate (PPS)
compared to placebo in participants with symptomatic kneE osteoarthritis
(OA) and dysLipidemia (MaRVeL Study)
https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000654853
Name
Arthropharm Pty Ltd
https://www.arthropharm.com.au/
- Forums
- ASX - By Stock
- research reports and media
Efficacy and safety of pentosan polysulfate sodium in people...
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
25.5¢ |
Change
-0.005(1.92%) |
Mkt cap ! $89.19M |
Open | High | Low | Value | Volume |
27.0¢ | 27.0¢ | 25.5¢ | $261.4K | 990.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9999 | 25.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.0¢ | 9445 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9999 | 0.255 |
5 | 259000 | 0.250 |
5 | 196000 | 0.245 |
9 | 261374 | 0.240 |
5 | 71970 | 0.235 |
Price($) | Vol. | No. |
---|---|---|
0.260 | 9445 | 1 |
0.275 | 44000 | 2 |
0.280 | 39900 | 5 |
0.285 | 6729 | 2 |
0.290 | 60000 | 2 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online